Loading...
India's valsartan imports from BANGLADESH total $41 across 6 shipments from 3 foreign suppliers. SQUARE PHARMACEUTICAL PLC. leads with $22 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include LAMBDA THERAPEUTIC RESEARCH LIMITED. This corridor reflects India's pharmaceutical import demand for valsartan — a concentrated sourcing relationship with select suppliers from BANGLADESH.
SQUARE PHARMACEUTICAL PLC. is the leading Valsartan supplier from BANGLADESH to India, with import value of $22 across 2 shipments. The top 5 suppliers — SQUARE PHARMACEUTICAL PLC., INCEPTA PHARMACEUTICALS LTD., INCEPTA PHARMACEUTICALS LTD — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SQUARE PHARMACEUTICAL PLC. | $22 | 2 | 53.9% |
| 2 | INCEPTA PHARMACEUTICALS LTD. | $12 | 2 | 30.0% |
| 3 | INCEPTA PHARMACEUTICALS LTD | $7 | 2 | 16.2% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | LAMBDA THERAPEUTIC RESEARCH LIMITED | $22 | 2 | 53.9% |
| 2 | SPINOS LIFE SCIENCE AND RESEARCH PRIVATE LIMITED | $12 | 2 | 30.0% |
| 3 | DHR HOLDING INDIA PRIVATE LIMITED |
BANGLADESH → India trade corridor intelligence
As of April 2026, the Bangladesh to India trade corridor for pharmaceutical imports is operating efficiently. Ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are functioning with minimal congestion. Freight rates remain stable, and the exchange rate between the Indian Rupee (INR) and Bangladeshi Taka is favorable for trade.
The Production Linked Incentive (PLI) scheme and import substitution policies are encouraging domestic manufacturing of pharmaceutical formulations, including Valsartan. These initiatives aim to reduce import dependency and promote self-reliance in the pharmaceutical sector.
India and Bangladesh share a robust trade relationship, with ongoing negotiations for Free Trade Agreements (FTAs) and mutual recognition of Good Manufacturing Practices (GMP). These efforts aim to facilitate smoother pharmaceutical trade and enhance bilateral cooperation.
| $7 |
| 2 |
| 16.2% |
The landed cost of importing Valsartan formulations from Bangladesh includes the Free on Board (FOB) price, freight charges, insurance, Basic Customs Duty (BCD), Social Welfare Surcharge (SWS), Integrated Goods and Services Tax (IGST), port handling fees, and Customs House Agent (CHA) charges. Per-unit estimates vary based on shipment size, packaging, and other factors.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Valsartan into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each Valsartan formulation must be registered with CDSCO, which involves submitting Form 40/41 along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The registration process typically takes 6 to 12 months. Valsartan formulations under HS Code 30049079 are subject to these requirements.
Imported Valsartan formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including ICH Zone IV studies, must be provided to demonstrate product stability under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products.
Between 2024 and 2026, CDSCO has implemented stricter regulations for importing finished pharmaceutical formulations, including Valsartan. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements with Bangladesh have been established to streamline trade procedures and ensure mutual recognition of Good Manufacturing Practices (GMP).
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Valsartan formulations to meet the demand for branded and specialized dosage forms not produced domestically. The market size for Valsartan formulations in India is substantial, driven by the prevalence of hypertension and heart failure. Imports supplement domestic production to fulfill the diverse needs of the Indian pharmaceutical market.
The Basic Customs Duty (BCD) on Valsartan formulations under HS Code 30049079 is 10%. An additional Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per the prevailing GST rates. There are no anti-dumping duties or exemptions for imports from Bangladesh. The total landed duty percentage varies based on the IGST rate and other applicable charges.
India sources Valsartan formulations from Bangladesh due to competitive pricing, quality manufacturing standards, and the availability of specialized dosage forms. Bangladesh's share in India's Valsartan import market is significant, offering advantages over other suppliers like China, Germany, and the US. The proximity and established trade relations further enhance Bangladesh's position as a preferred supplier.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Valsartan formulations from Bangladesh due to the availability of specialized dosage forms, competitive pricing, and adherence to international quality standards. Bangladesh's manufacturing capabilities and established trade relations make it a strategic source for these formulations.
Compared to other origins like China, the EU, and the US, Bangladesh offers advantages in terms of cost-effectiveness, quality compliance, and regulatory alignment with Indian standards. These factors contribute to Bangladesh's unique position in supplying Valsartan formulations to India.
Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. Past shortages have been minimal, but importers should maintain contingency plans to mitigate these risks.
Import license checklist, document requirements, quality testing, and compliance
CDSCO port inspectors conduct mandatory batch testing of imported Valsartan formulations. Samples are collected upon arrival, and testing is performed to verify compliance with Indian standards. If a batch fails, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance. Common quality issues from Bangladesh include labeling discrepancies and minor deviations in dissolution profiles.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Valsartan suppliers from BANGLADESH to India include SQUARE PHARMACEUTICAL PLC., INCEPTA PHARMACEUTICALS LTD., INCEPTA PHARMACEUTICALS LTD. The leading supplier is SQUARE PHARMACEUTICAL PLC. with import value of $22 USD across 2 shipments. India imported Valsartan worth $41 USD from BANGLADESH in total across 6 shipments.
India imported Valsartan worth $41 USD from BANGLADESH across 6 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Valsartan sourced from BANGLADESH include LAMBDA THERAPEUTIC RESEARCH LIMITED, SPINOS LIFE SCIENCE AND RESEARCH PRIVATE LIMITED, DHR HOLDING INDIA PRIVATE LIMITED. The largest buyer is LAMBDA THERAPEUTIC RESEARCH LIMITED with $22 in imports across 2 shipments.
The total value of Valsartan imports from BANGLADESH to India is $41 USD, across 6 shipments and 3 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
6 Verified Shipments
3 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists